LEGN - Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
As of Oct 14, 2026: spot at $19.17, ATM IV 68.7%, max pain $20.00, net GEX $194.9K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $3.31B
- Beta
- 0.40
- 52-Week Range
- 16.24-37.5
- CEO
- Alan S. Bash
- Employees
- 3,200
- IPO Date
- Jun 5, 2020
- Exchange
- NASDAQ
What LEGN Looks Like to Options Traders Today
IV rank of 9.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($194.9K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.019) is roughly flat across the wings.
What This Page Covers
The LEGN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LEGN overview questions
- What is LEGN?
- LEGN is the ticker symbol for Legend Biotech Corporation, a listed security. Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). Listed on NASDAQ. LEGN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the LEGN options snapshot look like today?
- As of Oct 14, 2026, the LEGN options snapshot shows spot at $19.17, ATM IV 68.7%, IV rank 9.8%, max pain $20.00, net GEX $194.9K, expected move 19.70%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are LEGN's key statistics?
- Legend Biotech Corporation (LEGN) carries a market capitalization of $3.31B, beta of 0.40 relative to the broader market, 52-week range of 16.24-37.5. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LEGN belong to?
- Legend Biotech Corporation operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LEGN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LEGN data on this page?
- The options snapshot above is dated Oct 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).